Researchers from Spain initiated the CogEval project, comparing high efficacy versus usual first-line treatment in patients with cognitive dysfunction, evaluated via Processing Speed Test (PST) [1]. The PST is a self-administered iPad®-based tool to measure MS-related deficits in processing speed and its use has shown an advantage over pen-and-paper cognitive batteries because of its ease of administration and a standardised scoring system.
The aim of CogEval is to determine whether early initiation of highly effective disease-modifying therapy (DMT) in patients with relapsing-remitting MS is associated with a decreased rate of longitudinal cognitive decline. Dr Andrés Labiano-Fontcuberta (University Hospital "12 de Octubre", Spain) presented the methods and objectives of this randomised open-label pilot study. Patients who are not under consideration for initiation of high-efficacy DMT but whose results on PST are below normal limits will be enrolled. Participants will randomly be allocated into 2 groups:
- experimental or intervention group, initiating highly-effective DMT (natalizumab, ocrelizumab, or alemtuzumab); and
- control group without intervention, which will continue with the conventional first-line treatment.
After a treatment period of 24 weeks, change from baseline PST and proportion of cognitive decline-free patients will be assessed. Recruitment is still ongoing.
- Labiano-Fontcuberta A. CogEval project: tackling unmet multiple sclerosis-related cognitive challenges. ECF 28th Annual Meeting. Abstract 41.
Posted on
Previous Article
« ECF 2020 Highlights Podcast Next Article
Reliable and convenient method to assess cognitive function in MS patients »
« ECF 2020 Highlights Podcast Next Article
Reliable and convenient method to assess cognitive function in MS patients »
Table of Contents: ECF 2020
Featured articles
ECF Round-Up Articles
No association between Ig levels and infection in ofatumumab-treated patients with relapsing MS
Defining phenotypes of MS-related cognitive impairment
First long-term efficacy data of a BTK inhibitor
Novel disease-specific scale confirms huge impact of fatigue
Progressive aerobic exercise improves fatigue
Reliable and convenient method to assess cognitive function in MS patients
Tackling unmet MS-related cognitive challenges
Real-world efficacy of ocrelizumab in MS patients
Similar demographics, clinical characteristics, and treatment patterns in German claims study
Decreased EDSS after plasma exchange in NMOSD
No support for IVIG as treatment of acute attacks in NMOSD
Related Articles
December 16, 2020
First long-term efficacy data of a BTK inhibitor
December 16, 2020
Defining phenotypes of MS-related cognitive impairment
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com